BR9607599A - Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon - Google Patents
Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferonInfo
- Publication number
- BR9607599A BR9607599A BR9607599A BR9607599A BR9607599A BR 9607599 A BR9607599 A BR 9607599A BR 9607599 A BR9607599 A BR 9607599A BR 9607599 A BR9607599 A BR 9607599A BR 9607599 A BR9607599 A BR 9607599A
- Authority
- BR
- Brazil
- Prior art keywords
- ifn
- con
- patient
- treating
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37247895A | 1995-01-13 | 1995-01-13 | |
| PCT/US1996/000323 WO1996021468A2 (en) | 1995-01-13 | 1996-01-11 | Chemically modified interferon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9607599A true BR9607599A (pt) | 1998-06-09 |
Family
ID=23468282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9607599A BR9607599A (pt) | 1995-01-13 | 1996-01-11 | Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0804248A2 (pt) |
| JP (1) | JPH10513440A (pt) |
| KR (1) | KR19980701814A (pt) |
| AU (1) | AU4751896A (pt) |
| BR (1) | BR9607599A (pt) |
| CA (1) | CA2209557A1 (pt) |
| IL (1) | IL116730A0 (pt) |
| WO (1) | WO1996021468A2 (pt) |
| ZA (1) | ZA96206B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305311A3 (en) * | 2001-10-10 | 2011-07-20 | BioGeneriX AG | Glycoconjugation of peptides |
| EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| PL1680137T3 (pl) | 2003-10-14 | 2013-04-30 | F Hoffmann La Roche Ltd | Makrocykliczny kwas karboksylowy i związek acylosulfonamidowy jako inhibitor replikacji HCV |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー／エス | グリコペグ化第ｉｘ因子 |
| EP2305696A3 (en) | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| KR20080056295A (ko) | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| AR078117A1 (es) | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
| US20080242607A1 (en) | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법 |
| MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| EP2459211A1 (en) | 2009-07-31 | 2012-06-06 | Medtronic, Inc. | Continuous subcutaneous administration of interferon- to hepatitis c infected patients |
| CN102711871A (zh) | 2010-06-16 | 2012-10-03 | 麦德托尼克公司 | 用于稳定药物递送装置中的药物的阻尼系统 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| KR950014915B1 (ko) * | 1991-06-19 | 1995-12-18 | 주식회사녹십자 | 탈시알로당단백-포함화합물 |
| TW263437B (pt) * | 1992-09-24 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| CN1087093A (zh) * | 1993-09-16 | 1994-05-25 | 华西医科大学药学院 | 肝靶向性的半乳糖基干扰素偶联物 |
-
1996
- 1996-01-10 IL IL11673096A patent/IL116730A0/xx unknown
- 1996-01-11 JP JP8521789A patent/JPH10513440A/ja active Pending
- 1996-01-11 BR BR9607599A patent/BR9607599A/pt unknown
- 1996-01-11 AU AU47518/96A patent/AU4751896A/en not_active Abandoned
- 1996-01-11 ZA ZA96206A patent/ZA96206B/xx unknown
- 1996-01-11 KR KR1019970705211A patent/KR19980701814A/ko not_active Application Discontinuation
- 1996-01-11 CA CA002209557A patent/CA2209557A1/en not_active Abandoned
- 1996-01-11 EP EP96903420A patent/EP0804248A2/en not_active Withdrawn
- 1996-01-11 WO PCT/US1996/000323 patent/WO1996021468A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2209557A1 (en) | 1996-07-18 |
| WO1996021468A2 (en) | 1996-07-18 |
| IL116730A0 (en) | 1996-05-14 |
| MX9705119A (es) | 1997-10-31 |
| EP0804248A2 (en) | 1997-11-05 |
| KR19980701814A (ko) | 1998-06-25 |
| JPH10513440A (ja) | 1998-12-22 |
| ZA96206B (en) | 1996-08-19 |
| AU4751896A (en) | 1996-07-31 |
| WO1996021468A3 (en) | 1996-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9607599A (pt) | Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon | |
| BR9602542A (pt) | Composto método para o tratamento de uma doença dependente da fosforilase de glicogénio composição farmacéutica e processo para a preparação de um composto | |
| BR9508586A (pt) | Compostos processo de preparação dos mesmos uso dos mesmos processo de tratamento de uma condição clínica em um mamífero e composição farmacêutica | |
| BR9611198A (pt) | Composto processo de preparação do mesmo e composição farmacêutica | |
| BR9606769A (pt) | Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete | |
| BR9609780A (pt) | Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto | |
| BR9604894A (pt) | Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo | |
| BR9405911A (pt) | Processo para a preparaçao de uma composiçao de copolímero em bloco e composiçao de copolímero em bloco | |
| BR9608405A (pt) | Composto composi-Æo farmaceutica e processo para tratar um paciente que sofre de um distÚrbio fisiolÄgico | |
| BR9407799A (pt) | Composição de matéria método de tratamento e composição farmaceutica | |
| BR9408148A (pt) | Processo para tratamento de arritmia composto e formulação farmacêutica | |
| BR9404114A (pt) | Composição farmacêutica e seu processo de preparação | |
| PT98944A (pt) | Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes | |
| PT952829E (pt) | Composicao farmaceutica de fenofibrato que apresenta uma biodisponibilidade elevada e seu modo de preparacao | |
| BR9611986A (pt) | Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos | |
| BR9407869A (pt) | Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose | |
| BR9406225A (pt) | Compósitos de matriz de titánio | |
| AU2187992A (en) | Composition and method for disease treatment | |
| BR9508237A (pt) | Composto derivado farmaceuticamente aceitável de um composto formulação farmacéutica uso de um composto método de tratamento ou prevenção dos sintomas ou efeitos de uma infecção por vírus em um animal infectado e processo para a preparação de um composto | |
| BR9503812A (pt) | Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto | |
| BR9707489A (pt) | Composto composição farmacêutica e processo para tratar um paciente sofrendo de um distúrbio fisilógico | |
| BR9100046A (pt) | Derivados de azaoxindole,composicao farmaceutica e processo para o tratamento de mamiferos | |
| BR9508732A (pt) | Métodos de inibição de desmielinação e de doenças desmielinativas | |
| BR9502471A (pt) | Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica | |
| BR9607346A (pt) | Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 47/48; A61K 38/21; C07K 14/56. Ipc: C07K 14/56 (2006.01), A61K 47/61 (2017.01), A61K 3 Ipc: C07K 14/56 (2006.01), A61K 47/61 (2017.01), A61K 3 |